Molecular and Cellular Research on Targets for Antimalarial Therapy Development

A special issue of Pathogens (ISSN 2076-0817). This special issue belongs to the section "Parasitic Pathogens".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 61

Special Issue Editor


E-Mail Website
Guest Editor
Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Rockville, MA, USA
Interests: malaria; antimalarial drug discovery; Ion channels and transporters; molecular biology; cell biology

Special Issue Information

Dear Colleagues,

Despite concerted efforts to develop chemotherapies and vaccines, nearly half of the world’s population remains at risk of malaria. In 2022, there were an estimated 249 million cases and 608,000 deaths, with Plasmodium falciparum and P. vivax being the primary causes of human disease. While the combined effects of indoor residual spraying, insecticide-treated bed nets, and artemisinin combination therapies reduced malaria incidence and mortality between 2000 and 2015, progress has subsequently stalled. Cases and deaths have both been increasing since 2019 due to insecticide and antimalarial drug resistance, disruptions due to the COVID-19 pandemic, and other factors. Due to acquired resistance mutations in the parasite, there is a desperate need to identify new targets for vaccine or antimalarial development. As unique mechanisms of action are especially desirable, molecular and cellular studies of the parasite and its interactions with the host and vector are needed.

In this Special Issue, we aim to provide a collection of timely research articles, comprehensive reviews, and short communications that relate to molecular and cellular malaria research with an emphasis on translation to much-needed therapies.

I look forward to your involvement in this important Special Issue.

Dr. Sanjay Arvind Desai
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • malaria
  • molecular biology
  • cellular biology
  • antimalarial drug discovery and development
  • malaria vaccines

Published Papers

This special issue is now open for submission.
Back to TopTop